4.7 Article

Targeted brain delivery of RVG29-modified rifampicin-loaded nanoparticles for Alzheimer's disease treatment and diagnosis

期刊

出版社

WILEY
DOI: 10.1002/btm2.10395

关键词

Alzheimer's disease; blood-brain barrier; brain targeting; MRI; rifampicin; beta-amyloid plaques

资金

  1. National Natural Science Foundation of China [81200930, 82071568]
  2. flagship specialty construction project of the First Affiliated Hospital of Jinan University-Department of Neurology [11001]
  3. Science and Technology Program of Guangzhou [202102010099]
  4. Guangdong Basic and Applied Basic Research Foundation [2022A1515010842]

向作者/读者索取更多资源

In this study, a brain-targeted nanomedicine was designed for the treatment of Alzheimer's disease. The results showed that the nanomedicine had favorable biocompatibility and could effectively reduce amyloid deposition, improve neuronal damage, and enhance learning and memory capability.
Alzheimer's disease (AD) is an aging-related neurodegenerative disease. The main pathological features of AD are beta-amyloid protein (A beta) deposition and tau protein hyperphosphorylation. Currently, there are no effective drugs for the etiological treatment of AD. Rifampicin (RIF) is a semi-synthetic broad-spectrum antibiotic with anti-13-amyloid deposition, anti-inflammatory, anti-apoptosis, and neuroprotective effects, but its application in AD treatment has been limited for its strong hydrophobicity, high toxicity, short half-life, low bioavailability, and blood-brain barrier hindrance. We designed a novel brain-targeted and MRI-characteristic nanomedicine via loading rabies virus protein 29 (RVG29), rifampicin, and Gd on poly (L-lactide) nanoparticles (RIF@PLA-PEG-Gd/Mal-RVG29). The cytotoxicity assay demonstrated that RIF@PLA-PEG-Gd/Mal-RVG29 had favorable biocompatibility and security. Fluorescence imaging in vivo showed that PLA-PEG-Gd/Mal-RVG29 could deliver rifampicin into the brain by enhancing cellular uptake and brain targeting performance, leading to improvement of the bioavailability of rifampicin. In in vivo study, RIF@PLA-PEG-Gd/Mal-RVG29 improved the spatial learning and memory capability of APP/PS1 mice in the Morris water maze, as compared to rifampicin. Immunofluorescence, TEM, immunoblotting, and H&E staining revealed that RIF@PLA-PEG-Gd/MalRVG29 reduced A beta deposition in hippocampal and cortex of APP/PS1 mice, improved the damage of synaptic ultrastructure, increased the expression level of PSD95 and SYP, as well as reduced the necrosis of neurons. These findings suggest that RIF@PLA-PEG-Gd/Mal-RVG29 may be an effective strategy for the treatment of AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据